SEC Form 4 · accession 0001237899-19-000007
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph L Goldstein
Director
Period of report
Jan 10, 2019
Accepted (ET)
Jan 11, 2019 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 10, 2019 | M | 1,791 | $273.67 | A | 14,114 | D | |
| Common Stock | Jan 10, 2019 | S | 1,791 | $410.00 | D | 12,323 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $273.67 | Jan 10, 2019 | M | 1,791 | D | — | Jan 2, 2024 | Common Stock | 1,791 | 0 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.